Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cancer therapy

Off-the-shelf CAR T cells for multiple myeloma

A study showing feasibility and preliminary efficacy of off-the-shelf CAR T cells represents steady progress on the long road to clinical use.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. Munshi, N. C. et al. N. Engl. J. Med. 384, 705–716 (2021).

    Article  CAS  Google Scholar 

  2. Martin, T. et al. J. Clin. Oncol. (2022).

    Article  Google Scholar 

  3. Delforge, M. et al. Blood Adv. 6, 1309–1318 (2022).

    Article  CAS  Google Scholar 

  4. Mailankody, S. et al. Nat. Med. (2023).

  5. Graham, C. E. et al. Leukemia 35, 3581–3584 (2021).

    Article  CAS  Google Scholar 

  6. Goodman, A. Patients with multiple myeloma may face CAR T-cell shortages. ASCO Post (25 September 2022).

  7. Benjamin, R. et al. Lancet Haematol 9, e833–e843 (2022).

    Article  Google Scholar 

  8. Ottaviano, G. et al. Sci. Transl. Med. 14, eabq3010 (2022).

    Article  CAS  Google Scholar 

  9. Berdeja, J. G. et al. Lancet 398, 314–324 (2021).

    Article  CAS  Google Scholar 

  10. Lonial, S. et al. Cancer 127, 4198–4212 (2021).

    Article  CAS  Google Scholar 

  11. Moreau, P. et al. N. Engl. J. Med. 387, 495–505 (2022).

    Article  CAS  Google Scholar 

  12. Sommer, C. et al. Blood 136, 8 (2020).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Jennifer N. Brudno.

Ethics declarations

Competing interests

J.N.B. is on the scientific advisory board for Kyverna Therapeutics, Inc. (unpaid position). J.N.K. receives royalties from Kite (a Gilead company), Celgene/Bristol Myers Squibb and Kyverna Therapeutics, Inc.; and research funding from Kite and Celgene/Bristol Myers Squibb.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Brudno, J.N., Kochenderfer, J.N. Off-the-shelf CAR T cells for multiple myeloma. Nat Med (2023).

Download citation

  • Published:

  • DOI:


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research